Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

156 results about "Liver targeting" patented technology

Liver Targeting. VLX103, is a novel oral form of pentamidine specifically designed to target the liver and minimize exposure to non-target, non-hepatic, organs and tissues.

Liver-targeting drug liposome and application thereof

The invention discloses a liver-targeting drug liposome and application thereof, and relates to the field of drug delivery, cholate and mannose are used for respectively modifying phospholipid molecules DSPE-PEG2000, two raw materials DSPE-PEG2000-CA and DSPE-PEG2000-MAN composed of the liposome are synthesized, and then the liposome is prepared into the liver-targeting drug liposome. The liposome with liver targeting property is obtained from the liposome, cholesterol, DSPC, DC-cholesterol and a water-soluble therapeutic drug according to a certain proportion, the liposome has relatively high cell safety and liver targeting property, and the therapeutic effect of the corresponding drug can be remarkably improved after the drug is embedded.
Owner:CHINA AGRI UNIV

Oral liver protection composition containing ergothioneine and preparation method thereof

The invention discloses a preparation method of an oral liver protection composition containing ergothioneine, and relates to the technical field of ergothioneine application. The oral liver protection composition containing the ergothioneine is prepared from the following components in parts by mass: 0.5 to 5 parts of the ergothioneine, 10 to 30 parts of silibinin, 20 to 50 parts of a phospholipid complex, 5 to 15 parts of a liver targeting carrier, 2 to 8 parts of a disintegrating agent, 1 to 5 parts of an adhesive and 2 to 4 parts of an antioxidant. Free radicals are efficiently captured through a polycyclic conjugated pi electron system of the antioxidant, a hydrogen bond network is formed by a heteroatom bridging effect of the antioxidant, a galactose group of the liver targeting carrier and the disintegrating agent, and the stability of the system is synergistically improved; the phospholipid complex is embedded with a hydrophobic drug and a hydrophilic carrier, and the drug is accurately delivered to the liver by combining the specific recognition capability of the liver targeting carrier; the ergothioneine and the silybin form a bidirectional synergistic liver protection mechanism by removing reactive oxygen free radicals and regulating and controlling cell signal channels respectively.
Owner:SHANGHAI ERGOTEIN BIOTECHNOLOGY GRP CO LTD

Sirna for inhibiting XDH gene expression and modifier and use thereof

Provided siRNA for inhibiting XDH gene expression and a modifier and use thereof. The siRNA comprises a sense strand and an antisense strand. The sense strand and / or the antisense strand have a length in the range of 19-25 nucleotides, and the antisense strand is reversely complementary to a segment on a target gene; and the sense strand has a nucleotide sequence as shown in SEQ ID NO: 1-14, and the antisense strand has a nucleotide sequence as shown in SEQ ID NO: 18-31. siRNA molecules and modified siRNA molecules have high stability and / or high inhibitory activity. Ligand-conjugated siRNA molecules have good liver targeting performance and the capability to promote cell endocytosis while maintaining high inhibitory activity and stability, can reduce the impact on other tissues or organs and reduce the amount of siRNA molecules used, and can achieve the purposes of reducing toxicity and reducing costs.
Owner:LIVZON PHARM GRP INC

Copper-based nano enzyme as well as preparation method and application thereof

The invention relates to the field of biomedicine, particularly provides a copper-based nano-enzyme as well as a preparation method and application thereof, and aims to solve the problems that in the prior art, clinical treatment on primary sclerosing cholangitis (PSC) is difficult in diagnosis and lacks of effective treatment drugs. The copper-based nano-enzyme comprises a nano-enzyme carrier and a copper-based nano-enzyme, wherein the nano-enzyme carrier is a two-dimensional nanosheet formed by copper ions, gallic acid and ursodesoxycholic acid through coordinate bonds; the probe molecule is a cyanine dye molecule connected to the surface of the nano-enzyme carrier through a covalent bond; wherein the fluorescence intensity of the copper-based nano enzyme is enhanced after the action of the alkaline phosphatase. The three functions of alkaline phosphatase responsive diagnosis, nano-enzyme catalytic treatment and ursodesoxycholic acid hepatic targeting are innovatively and synergistically integrated into one nano platform, the treatment function can be executed while specific imaging diagnosis is performed on diseases, and a new strategy is provided for diagnosis and treatment of diseases such as PSC.
Owner:SOUTH CHINA UNIV OF TECH

Exosome fusion liver targeting liposome drug delivery system as well as preparation method and application thereof

The invention relates to an exosome fusion liver targeting liposome drug delivery system as well as a preparation method and application thereof, and belongs to the field of high polymer material science and pharmaceutical preparations. The invention discloses an exosome-fused liver-targeted liposome drug delivery system, which combines high-concentration PEG8000 and Nycodenz in a breakthrough manner, synergistically improves the fusion efficiency of exosome and liposome, and forms bionic vesicles with uniform size and high drug loading capacity. The exosome not only can exert the anti-inflammatory and anti-oxidation characteristics, but also plays a role in resisting a severe gastrointestinal environment and crossing a biological barrier. In addition, liposome is modified by cholic acid derivatives through EDC / NHS mediated amidation reaction, precise targeting of the liver is achieved, and the liposome is fully accumulated in the liver. The effects synergistically realize the treatment of type II diabetes and non-alcoholic steatohepatitis.
Owner:CHINA PHARM UNIV

ROS (reactive oxygen species) response type persulfide biomacromolecule nano prodrug, nano preparation as well as preparation method and application of ROS response type persulfide biomacromolecule nano prodrug

The invention relates to an ROS response type persulfide biomacromolecule nano prodrug, a nano preparation and a preparation method and application of the ROS response type persulfide biomacromolecule nano prodrug and the nano preparation, and belongs to the technical field of nano preparations. According to the invention, the hydrogen persulfide is protected by utilizing ROS to respond to a small molecule group, so that the defect that the existing hydrogen persulfide is unstable is overcome; meanwhile, biomacromolecules are used as a carrier of the hydrogen persulfide, so that the liver targeting property, the water solubility and the biological safety of the hydrogen persulfide are improved, and multi-site modification and adjustability of the drug loading capacity are realized; in addition, the nano preparation is simple in reaction process, mild in condition and beneficial to clinical transformation.
Owner:OCEAN UNIV OF CHINA

Photodynamic combined active oxygen response type tripterine polymer micelle as well as preparation method and application thereof

The invention provides a photodynamic combined active oxygen response type tripterine polymer micelle as well as a preparation method and application thereof, and belongs to the technical field of medicines. According to the present invention, the photodynamic therapy is combined, the photosensitizer Ce6 and the antitumor drug Cela are co-entrapped in the reactive oxygen species (ROS)-responsive liver targeting polymer micelle, and the prepared drug-loaded micelle has characteristics of small particle size and high stability. When the photosensitizer absorbs exogenous visible-near infrared light energy, ROS free radicals can be generated, the ROS concentration of a tumor site is improved, the breaking speed of ketal thiol bonds in the micelle is accelerated, and drug release is accelerated. The polymer micelle drug-loading system is good in biological safety, has the ROS response type drug release characteristic, gives full play to the synergistic effect in combination with the photodynamic therapy, prolongs the residence time in the body, enhances the targeting to liver tumors, improves the bioavailability and the anti-tumor effect of Cela, reduces the toxic and side effects on healthy tissues and visceral organs, and has a good application prospect. And a better anti-tumor synergistic treatment effect is exerted.
Owner:FUJIAN UNIV OF TRADITIONAL CHINESE MEDICINE

Galactose modified liver targeting mesoporous silica material, preparation method and application

The invention belongs to the field of biological medicine, and particularly relates to a galactose modified liver targeting mesoporous silica material, a preparation method and application. Mesoporous silica is prepared through a hydrothermal synthesis method, modification is carried out through amino, disulfide bonds, graphene quantum dots and amino-terminated PEG chain galactose, a multifunctional drug carrier (PEG-Gal-MSNs-SS-GQDs) with the redox response release function is prepared, meanwhile, leech active peptide GFAGDDAPRA (GA-10) is loaded into a mesoporous channel, liver targeting release of drugs is achieved, and the liver targeting effect is achieved. The material loaded with the GA-10 has good redox response release characteristics and blood fat reducing activity. The PEG-Gal-MSN-SS-GQDs disclosed by the invention have a wide application prospect, and a new thought is provided for research on application of mesoporous silica in peptide drug loading and blood fat reduction.
Owner:BINZHOU MEDICAL COLLEGE

GalNAc monomer containing ribose ring or derivative structure thereof and application of GalNAc monomer in hepatic targeting delivery of small nucleic acid drugs

The invention provides a GalNAc monomer containing a ribose ring or a derivative structure of the ribose ring and application of the GalNAc monomer in hepatic targeting delivery of small nucleic acid drugs. A compound of formula (I) or a pharmaceutically acceptable salt thereof is provided. According to the GalNAc-conjugated oligonucleotide prepared by the GalNAc compound provided by the invention, efficient liver targeting delivery can be realized, and the drug curative effect is improved. # imgabs0 #
Owner:BEIJING YUEKANGKECHUANG PHARM TECH CO LTD

Liver-targeted three-antenna GalNAc connexon precursor and preparation method thereof

The invention relates to a GalNAc connexon precursor and a preparation method thereof, in particular to a preparation method of a liver targeting three-antenna GalNAc connexon precursor with a structure shown in a formula 13. The method provided by the invention has the advantages of few steps, simple purification, high yield and mild reaction conditions, and is suitable for industrial production.
Owner:SHANGHAI INST OF PHARMA IND CO LTD +1

GalNAc compound containing triazole structure and oligonucleotide conjugate thereof

The present invention provides a GalNAc compound containing a triazole structure and an oligonucleotide conjugate thereof, specifically disclosing a GalNAc compound as shown in formula (I) or a pharmaceutically acceptable salt thereof. The GalNAc compound in the present invention can form a conjugate with an oligonucleotide, and the conjugate can achieve efficient liver-targeted delivery of the oligonucleotide, regulate gene expression, and can be used to prevent and / or treat diseases caused by the expression of specific genes in liver cells. #imgabs0#
Owner:BEIJING YUEKANGKECHUANG PHARM TECH CO LTD

Multi-stage liver-targeted drug delivery system based on ionizable amino lipid and preparation method of multi-stage liver-targeted drug delivery system

The invention discloses a multilevel liver targeting drug delivery system based on ionizable amino lipid and a preparation method thereof, the system comprises the following components: target modified ionizable amino lipid, ionizable amino lipid, auxiliary lipid and structural lipid in a molar ratio of (10-30): (30-60): (5-40): (15-55), according to the system, nano lipid particles exist in a water-in-oil-in-water nano emulsion form; wherein the ionizable ammonia lipid is a compound with a structure as shown in a formula (I). The system is suitable for delivering nucleic acid, protein and other active pharmaceutical ingredients to the liver so as to improve the accuracy and treatment effect of drug delivery and reduce the side effects of non-target organs.
Owner:YANGTZE RIVER DELTA MEDICAL ADVANCED TECHNOLOGY INNOVATION CENTER

THR-β receptor agonist, preparation method therefor, and use method therefor

Disclosed in the present invention are a THR-β receptor agonist, a preparation method therefor, and a use method therefor. The present invention provides a compound represented by formula (I), and a pharmaceutically acceptable salt or stereoisomer thereof. The agonist of the present invention has better THR-β agonistic activity and selectivity and strong liver-targeting ability, and can be used in metabolic diseases (such as non-alcoholic steatohepatitis (NASH), hepatic steatosis, hyperlipidemia, and obesity), cardiovascular diseases (such as atherosclerosis), and thyroid diseases (such as hypothyroidism and thyroid cancer).
Owner:CVI PHARMACEUTICALS SHANGHAI LTD

Tandem double-locking liver targeting fluorescent probe as well as preparation method and application thereof

The invention discloses a tandem double-locking liver targeting fluorescent probe as well as a preparation method and application thereof. The probe is a compound LDMTY. Through experiments, the applicant finds that the probe shows high sensitivity and selectivity to HClO and beta-gal, the lowest detection limits reach 0.046 mu M and 2.54 * 10 <-4 > U / mL respectively, overexpression of HClO and beta-gal in HCC can be recognized at the same time, the capacity of targeting and accumulating in the liver is achieved, hepatocellular carcinoma can be accurately detected, and the application prospect is wide. And promising potential and value are shown in the aspect of HCC detection.
Owner:THE FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY

Curcumin composite particles for improving alcohol-related liver diseases and preparation method of curcumin composite particles

The invention provides curcumin composite particles for improving alcohol-related liver diseases and a preparation method of the curcumin composite particles, and belongs to the technical field of nutritional active ingredient delivery systems. According to the preparation method, zein is taken as a core carrier, curcumin encapsulation is realized through an anti-solvent precipitation method, a compact gel middle layer is constructed by further adopting the protection performance of carrageenan and combining calcium ion mediated ionic crosslinking, and then the outer layer is coated with galactosylated chitosan with liver targeting property through electrostatic adsorption, so that the curcumin-containing hydrogel is prepared. And the curcumin-zein-carrageenan-galactosylated chitosan composite particle with a core-shell-shell structure is innovatively constructed. Compared with free curcumin, the composite particle has obviously improved light and heat stability, realizes controlled release of curcumin in a gastrointestinal tract environment, exerts an effect of obviously improving the alcohol-related liver disease, and has a good application prospect in the aspect of development of functional products for preventing and treating the alcohol-related liver disease.
Owner:WUHAN UNIV

Liver targeting lipid carrier as well as preparation method and application thereof

The invention discloses a lipid carrier for targeting liver and a preparation method and application thereof, and relates to the field of drug delivery, cholate and mannose are respectively used for modifying two raw materials, namely DSPE-PEG-CA and DSPE-PEG-MAN, consisting of phospholipid molecules DSPE-PEG2000 and synthetic lipidosome, and then the two raw materials, cholesterol, DSPC, DC-cholesterol and the like are mixed according to a certain proportion to obtain the lipid carrier with liver targeting property. The liposome disclosed by the invention has relatively high cell safety and liver targeting property.
Owner:CHINA AGRI UNIV

Liver targeting porous starch-luteolin compound as well as preparation method and application thereof

The invention discloses a liver targeting porous starch-luteolin compound and a preparation method and application thereof, and belongs to the technical field of drug delivery, corn porous starch is used as a carrier, and the compound with the liver targeting function is prepared through OSA hydrophobic modification, luteolin loading and epsilon-polylysine-galactoside targeting modification. The drug loading capacity and liver targeting property of luteolin are remarkably improved through triple modification, the production process is simple, the cost is low, and excellent blood sugar reducing and liver protecting effects are shown in diabetes liver injury treatment.
Owner:YANCHENG INST OF TECH

Pharmaceutical composition and application thereof in preparation of medicines for treating hepatic diseases

The invention discloses a pharmaceutical composition. The pharmaceutical composition is characterized in that the pharmaceutical composition comprises a carrier compound, the carrier compound is formed by an exosome and a lipid substance or a cationic polymer through positive and negative charge attraction, and the carrier compound further comprises an active pharmaceutical ingredient nucleic acid, the pharmaceutical composition also optionally comprises a pharmaceutically applicable carrier. The pharmaceutical composition enables delivery of nucleic acids. Therefore, hepatic targeting expression of nucleic acid is realized, and the survival rate of individuals suffering from hepatic diseases (such as an acute hepatic failure model and hepatic fibrosis) is improved.
Owner:HEXAELL BIOTECH

A GalNAc compound containing a ribose ring or its derivative structure and its oligonucleotide conjugate

The present invention provides a GalNAc compound containing a ribose ring or its derivative structure and an oligonucleotide conjugate thereof. With the oligonucleotide conjugate provided by the present invention, efficient liver-targeted delivery can be achieved, improving the drug efficacy.
Owner:HANGZHOU TIANLONG PHARM CO LTD

A liver-targeted gene editing system based on endogenous promoter hijacking and application thereof

The application discloses a liver-targeted gene editing system based on endogenous promoter hijacking and application, and belongs to the field of biological medicine. The system is composed of an LNP-wrapped modified Cas nuclease mRNA (first component) and a promoter-free viral vector carrying a therapeutic transgene donor (second component). The system uses LNP to realize the transient burst expression of Cas nuclease in the liver, mediates the generation of double-strand breaks at the site of endogenous high-expression genes, induces the site-specific integration of therapeutic transgenes without exogenous promoters, and hijacks the expression driven by endogenous promoters by using the splice acceptor (SA) mechanism. The application solves the risk of carcinogenesis caused by random integration of exogenous strong promoters and the immunotoxicity of long-term expression of nucleases through a "double safety lock" design. Experimental results prove that the system has high editing efficiency, long-term stability and no off-target, and can be used for various liver-derived metabolic diseases such as hemophilia, hypercholesterolemia and the like.
Owner:INST OF HEMATOLOGY & BLOOD DISEASES HOSPITAL CHINESE ACADEMY OF MEDICAL SCI & PEKING UNION MEDICAL COLLEGE

Pharmaceutical composition containing hiHeps-derived exosome and application thereof

The invention discloses a pharmaceutical composition containing a hiHeps-derived exosome, an application of the pharmaceutical composition or the hiHeps-derived exosome in preparation of a medicine for treating liver diseases, and an application of the pharmaceutical composition or the hiHeps-derived exosome in preparation of a medicine for reducing inflammation. The pharmaceutical composition comprises an exosome, a liposome and a nucleic acid drug, wherein the exosome is derived from hiHeps. The pharmaceutical composition can realize better nucleic acid delivery, has lower immunotoxicity and better biocompatibility compared with single cationic liposome delivery, and can efficiently realize expression and functions in in-vitro cell lines, primary hepatocytes and in-vivo mice. Compared with other exosomes, the pharmaceutical composition constructed by the hiHeps exosome also has higher liver targeting property and parenchymal hepatic cell targeting property.
Owner:SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES +1

Immature bitter orange extracellular vesicle-like particle as well as preparation method and application thereof

The invention belongs to the technical field of traditional Chinese medicines, and discloses an immature bitter orange-derived extracellular vesicle-like nanoparticle, which is characterized in that the immature bitter orange-derived extracellular vesicle-like nanoparticle is prepared by the steps of crushing immature bitter orange, filtering, centrifuging and resuspending, the average particle size is 60-120 nm, and the particle size of the immature bitter orange-derived extracellular vesicle-like nanoparticle is 20-30 nm. The extracellular vesicle-like nanoparticles are used for entrapment of at least one of naringin, neohesperidin, naringenin and hesperidin. The extracellular vesicle-like nanoparticles derived from immature bitter oranges are simple in preparation method, have liver targeting and good stability, and can be used for preparing medicines for preventing and / or treating liver injury, depression and breast cancer.
Owner:GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE

Preparation method of liver-targeted chemotherapeutic drug nano-micelle, chemotherapeutic drug and application

The invention relates to the technical field of medical application, in particular to a liver-targeted chemotherapeutic drug nano-micelle preparation method, a chemotherapeutic drug and application, and the preparation method comprises the following steps: S100, preparing pluronic-succinimide formate; s200, preparing a pluronic-polyethyleneimine copolymer; s300, preparing divinyl sebacate; carrying out enzymatic synthesis on the Pluronic F127-SE; the preparation method comprises the following steps: preparing a Pluronic F127-C8-GalNAc nano micelle; and preparing the GalNAc (at) LFT-MMs / siCOP1 compound. The preparation method disclosed by the invention is beneficial to rapidly preparing the nano-micelle with multiple effects of active targeting, chemotherapy and gene therapy.
Owner:CHINESE PEOPLES LIBERATION ARMY XINJIANG MILITARY REGION GENERAL HOSPITAL

Liver-targeting nitric oxide donor compound and application thereof

The invention discloses a liver-targeting nitric oxide donor compound and application thereof. The compound is a derivative of 5-isosorbide mononitrate, and can be enriched in the liver and release nitric oxide. Compared with 5-isosorbide mononitrate, the compound disclosed by the invention is easier to metabolize after primary hepatocyte incubation of mice, effectively releases effector molecules such as nitric oxide and the like, shows good liver targeting, is expected to play a better effect in treatment of liver-related diseases, and improves the clinical application value of drugs.
Owner:SHENZHEN BORUI PHARM TECH CO LTD

GalNAc compound coupled nucleic acid lipid nanoparticle containing ribose ring structure as well as preparation method and application of GalNAc compound coupled nucleic acid lipid nanoparticle

The invention provides GalNAc compound coupled nucleic acid lipid nanoparticles containing a ribose ring structure as well as a preparation method and application of the GalNAc compound coupled nucleic acid lipid nanoparticles. The lipid nanoparticle comprises the following components: nucleic acid, lipid and an anchoring compound of GalNAc containing a ribose ring, the lipids comprise cationic lipids, neutral lipids, auxiliary lipids and long-circulating lipids; the anchoring compound of the GalNAc containing the ribose ring comprises a GalNAc part containing the ribose ring and an lipid chain group, the structural formula of the anchoring compound is shown as a formula IX. The conjugate provided by the invention can realize efficient liver targeting delivery, and improves the curative effect of the drug.
Owner:BEIJING YUEKANGKECHUANG PHARM TECH CO LTD

Preparation method of liver-targeted drug-loaded liposome

The invention provides a preparation method of liver-targeted drug-loaded liposome, and belongs to the field of biological medicine. The hepatic targeting carbohydrate chain is constructed through a multi-step enzymatic reaction, and the accuracy of a modification site is ensured. The synthesized galactose ligand is connected to the surface of the liposome through a covalent bond, so that the targeting property and the stability are enhanced. The synthesis of the galactose ligand provides targeting functional groups with clear structures for the liposome, and the groups are integrated to the surface of the liposome through physical entrapment and chemical coupling in the preparation of the liposome, so that active targeting delivery is finally realized. The collaborative design of the two is based on an ASGPR-mediated liver targeting mechanism, and the delivery efficiency is optimized through enzymatic synthesis and a nanotechnology. In in vivo experiments, plasma and liver distributions of liposomes are determined. In an in-vitro experiment, the uptake efficiency of the lipidosome in liver cancer cells is determined. The experiments aim at verifying that the advantages of the lipidosome in liver cancer cell delivery are improved by optimizing the PEG chain length and the exposure of residues.
Owner:JIAYING UNIV

A method for modifying phospholipids and its use in the preparation of liver-targeted liposomes

The application discloses a method for modifying phospholipids and application thereof in preparation of liver-targeted liposomes, relates to the field of drug delivery, and first utilizes cholate and mannose to modify phospholipid molecules DSPE-PEG 2000 respectively 2000 Two raw materials DSPE-PEG 2000 -CA and DSPE-PEG 2000 -MAN for synthesizing liposomes are synthesized, and then cholesterols, DSPC and DC-cholesterols are added in a certain proportion to obtain liposomes with liver targeting property, which have high cell safety and liver cell targeting property.
Owner:CHINA AGRI UNIV

AAV8 capsid variants with enhanced liver targeting

The present disclosure provides variant AAV8 capsids that exhibit altered capsid properties, e.g., improved transduction efficiency and / or specificity for the liver. The present disclosure further provides nucleic acids encoding the variant AAV8 capsids, recombinant AAV (rAAV) vectors comprising the variant AAV8 capsids, as well as host cells and compositions comprising the same. The present disclosure further provides methods of delivering a gene product to a subject and methods of treatment of a liver-borne blood disorder, the methods generally involving administering an effective amount of the rAAV vectors to a subject in need thereof.
Owner:TAKEDA PHARMA CO LTD +2

Liver-targeted self-assembly liver protection peptide and application thereof in preparation of medicine for treating alcoholic liver injury

The invention belongs to the field of medicines, and particularly relates to a hepatic targeting self-assembly liver protection peptide and application thereof in preparation of a medicine for treating alcoholic liver injury. According to the present invention, the prepared liver targeting self-assembly liver protection peptide FFGGHKDYNDLLDR can be formed through the formation of nanoparticles; the nanoparticles can be orally administered, maintain a stable sequence and structure in a gastric acid environment with a pH value of 2, prevent the influence of a complex enzyme environment in intestinal tracts, are released in a body fluid system after being absorbed by the intestinal tracts, and are enriched in the liver under the action of a liver targeting module in the liver targeting self-assembly liver protection peptide, so that the alcoholic liver injury is effectively inhibited.
Owner:WENZHOU JINXI VALLEY AGRI DEV CO LTD